Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
This multicenter cohort study found that patients with cancer who received prophylactic IV magnesium before initiating treatment with IV cisplatin had a lower risk of CP-AKI compared to those who did not receive magnesium. Randomized clinical trials are needed to confirm these findings.
Authors
- Matthew H. Abramson (ORCID: https://orcid.org/0000-0002-7805-2287)
- Kenar D. Jhaveri (ORCID: https://orcid.org/0000-0003-1578-0524)
- David E. Leaf (ORCID: https://orcid.org/0000-0001-7875-090X)
- Raphael C. Kim (ORCID: https://orcid.org/0000-0002-0387-5107)
- Jamie S. Hirsch (ORCID: https://orcid.org/0000-0001-9571-1275)
- Sophia L. Wells
- Ala Abudayyeh (ORCID: https://orcid.org/0000-0002-5813-6299)
- Melanie S. Joy (ORCID: https://orcid.org/0000-0002-3887-004X)
- Shruti Gupta (ORCID: https://orcid.org/0000-0002-5747-2151)
- Marta Pirovano (ORCID: https://orcid.org/0000-0002-9737-7052)
- Ilya Glezerman (ORCID: https://orcid.org/0000-0002-2212-9097)
- Anukul Ghimire (ORCID: https://orcid.org/0000-0001-9165-4920)
- Kevin L. Chen (ORCID: https://orcid.org/0000-0002-3316-2212)
- Api Chewcharat (ORCID: https://orcid.org/0000-0002-1707-9988)
- Anip Bansal
- Valda D. Page
- Jessica L. Ortega (ORCID: https://orcid.org/0009-0004-2713-5471)
Institutions
- Brigham and Women's Hospital (US)
- Northwell Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Cornell University (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Dana-Farber Cancer Institute (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Montana (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1001/jamaoncol.2025.0756
- Citations
- 21
- Primary Topic
- Chemotherapy-induced organ toxicity mitigation
- Type
- article
- Field-Weighted Citation Impact
- 30.90